The estimated Net Worth of John L Lamattina is at least $3.46 Milion dollars as of 16 November 2021. John Lamattina owns over 4,835 units of Ligand Pharmaceuticals stock worth over $3,116,720 and over the last 21 years he sold LGND stock worth over $0. In addition, he makes $342,400 as Independent Director at Ligand Pharmaceuticals.
John has made over 10 trades of the Ligand Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 4,835 units of LGND stock worth $156,171 on 16 November 2021.
The largest trade he's ever made was buying 10,000 units of Ligand Pharmaceuticals stock on 11 March 2011 worth over $98,000. On average, John trades about 887 units every 132 days since 2004. As of 16 November 2021 he still owns at least 30,233 units of Ligand Pharmaceuticals stock.
You can see the complete history of John Lamattina stock trades at the bottom of the page.
Dr. John L. Lamattina Ph.D. serves as Independent Director of the Company. He spent 30 years at Pfizer Inc. with his last position starting in 2004 as President, Pfizer Global R&D. Dr. LaMattina began his career at Pfizer as a medicinal chemist in 1977. During his career, he was appointed to various positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery Operations in 1993, Senior Vice President of Worldwide Discovery Operations in 1998, Senior Vice President of Worldwide Development in 1999. Dr. LaMattina graduated with cum laude honors from Boston College with a B.S. in Chemistry. He received a Ph.D. from the University of New Hampshire in Organic Chemistry and subsequently was at Princeton University in the National Institutes of Health Postdoctoral Fellowship program. Dr. LaMattina is currently a senior partner at PureTech Ventures and serves on the boards of directors of Zafgen, Inc, a publicly-traded biotechnology company, and several privately-held biopharmaceutical companies.
As the Independent Director of Ligand Pharmaceuticals, the total compensation of John Lamattina at Ligand Pharmaceuticals is $342,400. There are 16 executives at Ligand Pharmaceuticals getting paid more, with John Higgins having the highest compensation of $6,770,380.
John Lamattina is 70, he's been the Independent Director of Ligand Pharmaceuticals since 2011. There are no older and 16 younger executives at Ligand Pharmaceuticals.
John's mailing address filed with the SEC is 555 HERITAGE DRIVE, SUITE 200, JUPITER, FL, 33458.
Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Ligand Pharmaceuticals executives and other stock owners filed with the SEC include: